Generation and Engineering of Potent Single Domain Antibody-based Bispecific IL-18 Mimetics Resistant to IL-18BP Decoy Receptor Inhibition
Overview
Authors
Affiliations
Here, we generated bispecific antibody (bsAb) derivatives that mimic the function of interleukin (IL)-18 based on single domain antibodies (sdAbs) specific to IL-18 Rα and IL-18 Rβ. For this, camelids were immunized, followed by yeast surface display (YSD)-enabled discovery of VHHs targeting the individual receptor subunits. Upon reformatting into a strictly monovalent (1 + 1) bispecific sdAb architecture, several bsAbs triggered dose-dependent IL-18 R downstream signaling on IL-18 reporter cells, as well as IFN-γ release by peripheral blood mononuclear cells in the presence of low-dose IL-12. However, compared with IL-18, potencies and efficacies were considerably attenuated. By engineering paratope valencies and the spatial orientation of individual paratopes within the overall design architecture, we were able to generate IL-18 mimetics displaying significantly augmented functionalities, resulting in bispecific cytokine mimetics that were more potent than IL-18 in triggering proinflammatory cytokine release. Furthermore, generated IL-18 mimetics were unaffected from inhibition by IL-18 binding protein decoy receptor. Essentially, we demonstrate that this strategy enables the generation of IL-18 mimetics with tailor-made cytokine functionalities.
Lipinski B, Unmuth L, Arras P, Endruszeit R, Becker S, Rodel J Protein Sci. 2025; 34(3):e70072.
PMID: 39981925 PMC: 11843475. DOI: 10.1002/pro.70072.
An engineered palivizumab IgG2 subclass for synthetic gp130 and fas-mediated signaling.
Wittich C, Ettich J, Hertell M, Roy B, Ghosh Roy B, Xu H J Biol Chem. 2025; 301(3):108205.
PMID: 39828098 PMC: 11872477. DOI: 10.1016/j.jbc.2025.108205.
IL-18 and IL-18BP: A Unique Dyad in Health and Disease.
Novick D Int J Mol Sci. 2025; 25(24.
PMID: 39769266 PMC: 11727785. DOI: 10.3390/ijms252413505.
Fernandez-Quintero M, Guarnera E, Musil D, Pekar L, Sellmann C, Freire F Protein Sci. 2024; 33(11):e5176.
PMID: 39422475 PMC: 11487682. DOI: 10.1002/pro.5176.
The present and future of bispecific antibodies for cancer therapy.
Klein C, Brinkmann U, Reichert J, Kontermann R Nat Rev Drug Discov. 2024; 23(4):301-319.
PMID: 38448606 DOI: 10.1038/s41573-024-00896-6.